Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.
Molecular Pathology
Molecular Tumor Board (MTB)
Next generation Sequencing (NGS)
Journal
Pathologica
ISSN: 1591-951X
Titre abrégé: Pathologica
Pays: Italy
ID NLM: 0401123
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
07
2021
accepted:
26
07
2021
pubmed:
1
9
2021
medline:
29
10
2021
entrez:
31
8
2021
Statut:
ppublish
Résumé
Next Generation Sequencing (NGS) is increasingly used in diagnostic centers for the assessment of genomic alterations to select patients for precision oncology. The Italian Society of Anatomic Pathology and Diagnostic Cytopathology (SIAPEC) through the Molecular Pathology and Predictive Medicine Study Group (PMMP) has been following the progressive development of centers that have adopted NGS technology in diagnostics over time. In July 2017, a study network on massive parallel sequencing was activated in Italy and recognized as the NGS SIAPeC National Network by the SIAPeC Scientific Society Board. Since then, activities have been implemented within the network that provide for alignment of laboratories through diagnostic concordance analysis and monitoring of centers adhering to the Network. Recently, considering the growing need for extended genomic analyses, the PMMP distributed a national survey to assess activities related to the use of genomic diagnostics in oncology within the NGS SIAPEC National Network. Thirty centers participated in the survey. Eighty percent of the centers are laboratories within Pathology Departments. The distribution of laboratories in the country, the diagnostic laboratory/population ratio, the staff dedicated, the type and number of sequencing and mechatronics platforms available, the genomic panels utilized, and the type and number of diagnostic tests carried out in the last year in each center, are reported. The centers were also asked whether they participated in a multidisciplinary Molecular Tumor Board (MTB) for management of patients. Thirty percent of the centers had a MTB that was ratified by regional decree. The professionals most frequently involved in the core team of the MTB are the pathologist, oncologist, molecular biologist, geneticist, pharmacologist, and bioinformatician. The data from this survey indicate that NGS diagnostics in Italy is still heterogeneous in terms of geographical distribution and the characteristics of laboratories and diagnostic test performed. The implementation of activities that favors harmonization, the logistics and the convergence of biological material in reference centers for molecular analyses is a priority for the development of a functional laboratory network.
Identifiants
pubmed: 34463674
doi: 10.32074/1591-951X-324
pmc: PMC8488986
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-271Informations de copyright
Copyright © 2021 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.
Références
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
BMC Med Genomics. 2021 Apr 14;14(1):105
pubmed: 33853586
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
J Clin Oncol. 2013 May 20;31(15):1806-14
pubmed: 23589557
J Pers Med. 2020 Nov 27;10(4):
pubmed: 33260805
J Pathol. 2020 Jan;250(1):19-29
pubmed: 31471895
Am J Health Syst Pharm. 2016 Dec 1;73(23):1935-1942
pubmed: 27864201
Oncotarget. 2017 Jun 14;8(34):57845-57854
pubmed: 28915716
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Oncologist. 2015 Sep;20(9):1011-8
pubmed: 26205736
Pathology. 2018 Jun;50(4):389-401
pubmed: 29752127
Virchows Arch. 2017 Jan;470(1):5-20
pubmed: 27678269
Virchows Arch. 2013 Jan;462(1):27-37
pubmed: 23250354
Clin Genet. 2018 Mar;93(3):533-544
pubmed: 29265354
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Adv Exp Med Biol. 2019;1168:9-30
pubmed: 31713162